John J P Kastelein

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Christina Lindahl, Nicholas J Wareham, Mogens Lytken Larsen, 2008, Journal of the American College of Cardiology.

Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.

A. Zwinderman, J. Kastelein, M. Trip, 2003, Archives of internal medicine.

The endothelial glycocalyx: a potential barrier between health and vascular disease

Hans Vink, Max Nieuwdorp, Joost B L Hoekstra, 2005, Current opinion in lipidology.

And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors

J. Kastelein, M. C. Meuwese, E. Stroes, 2006, Current opinion in lipidology.

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.

J. Kastelein, E. Stroes, Erik S G Stroes, 2005, Journal of the American College of Cardiology.

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Ming-Dauh Wang, M. Shao, J. Kastelein, 2011, JAMA.

Controversies in cardiovascular medicine C-reactive protein is a mediator of cardiovascular disease

J. Kastelein, S. Boekholdt, E. Stroes, 2010 .

Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease

Hans Vink, Max Nieuwdorp, J. Kastelein, 2009, Current opinion in lipidology.

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

D. Rader, J. Kastelein, Daniel J Rader, 2014, Circulation.